Outcomes
SARS-CoV-2 infection
ADVERSE EVENTS, SECONDARY, ADVERSE EVENT, SARS-COV-2 INFECTION
The primary outcome measures pertained to efficacy and safety of HCQ to prevent SARS-CoV-2 infection up to 4 weeks after randomisation. The primary efficacy endpoint was a positive polymerase chain reaction (PCR) or serological test for SARS-CoV-2 and the primary safety endpoint was grade 3 or greater adverse event during follow-up. The secondary outcome concerned the tolerability of the prophylactic treatment and was measured as the proportion of participants opting out of treatment due to the presence of grade 1 or 2 adverse events.